Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Cash from Operations (2020 - 2025)

Historic Cash from Operations for SAB Biotherapeutics (SABSW) over the last 6 years, with Q3 2025 value amounting to -$13.1 million.

  • SAB Biotherapeutics' Cash from Operations fell 10740.56% to -$13.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$37.5 million, marking a year-over-year increase of 176.82%. This contributed to the annual value of -$34.3 million for FY2024, which is 3651.6% down from last year.
  • As of Q3 2025, SAB Biotherapeutics' Cash from Operations stood at -$13.1 million, which was down 10740.56% from -$7.2 million recorded in Q2 2025.
  • Over the past 5 years, SAB Biotherapeutics' Cash from Operations peaked at $9.5 million during Q1 2021, and registered a low of -$13.4 million during Q4 2023.
  • Moreover, its 5-year median value for Cash from Operations was -$6.4 million (2021), whereas its average is -$5.7 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first plummeted by 4852608.65% in 2021, then skyrocketed by 8316.46% in 2023.
  • SAB Biotherapeutics' Cash from Operations (Quarter) stood at -$4.9 million in 2021, then soared by 68.12% to -$1.6 million in 2022, then tumbled by 764.73% to -$13.4 million in 2023, then increased by 29.11% to -$9.5 million in 2024, then plummeted by 36.9% to -$13.1 million in 2025.
  • Its Cash from Operations stands at -$13.1 million for Q3 2025, versus -$7.2 million for Q2 2025 and -$7.8 million for Q1 2025.